Perceived efficacy of salbutamol by persons with spinal muscular atrophy: A mixed methods study

Muscle and Nerve

Volumn 54, Issue 5, 2016, Pages 843-849

  Giovannetti, Ambra M ^a   Pasanisi, Maria Barbara ^a   Černiauskaitė, Milda ^a   Bussolino, Chiara ^a   Leonardi, Matilde ^a   Morandi, Lucia ^a  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

disability; fatigue; mixed methods study; patient reported outcome; qualitative study; salbutamol

Indexed keywords

SALBUTAMOL; BRONCHODILATING AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; DISABILITY; DIZZINESS; DRUG EFFICACY; FATIGUE; FATIGUE SEVERITY SCALE; FEMALE; HEART RATE; HUMAN; INTERNATIONAL CLASSIFICATION OF FUNCTIONING, DISABILITY AND HEALTH; LONGITUDINAL STUDY; MALE; MIDDLE AGED; PERCEPTION; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SEMI STRUCTURED INTERVIEW; SPINAL MUSCULAR ATROPHY; THEMATIC ANALYSIS; TREMOR; MUSCULAR ATROPHY, SPINAL; NONPARAMETRIC TEST; QUESTIONNAIRE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADULT; ALBUTEROL; BRONCHODILATOR AGENTS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MUSCULAR ATROPHY, SPINAL; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; SURVEYS AND QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 84991753326     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.25102     Document Type: Article

References (27)

1. Pearn J. Incidence, prevalence, and gene frequency studies of chronic childhood spinal muscular atrophy. J Med Genet 1978;15:409–413.
2. Kinali M, Mercuri E, Main M, De Biasia F, Karatza A, Higgins R, et al. Pilot trial of albuterol in spinal muscular atrophy. Neurology 2002;59:609–610.
3. Zerres K, Davies KE. 59th ENMC International Workshop: Spinal Muscular Atrophies: recent progress and revised diagnostic criteria 17–19 April 1998, Soestduinen, The Netherlands. Neuromuscul Disord 1999;9:272–278.
4. Mercuri E, Bertini E, Iannaccone ST. Childhood spinal muscular atrophy: controversies and challenges. Lancet Neurol 2012;11:443–452.
5. Kolb SJ, Kissel JT. Spinal muscular atrophy. Neurol Clin 2015;33:831–846.
6. Lefebvre S, Bürglen L, Reboullet S, Clermont O, Burlet P, Viollet L, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995;80:155–165.
7. Frugier T, Tiziano FD, Cifuentes-Diaz C, Miniou P, Roblot N, Dierich A, et al. Nuclear targeting defect of SMN lacking the C-terminus in a mouse model of spinal muscular atrophy. Hum Mol Genet 2000;9:849–858.
8. Lefebvre S, Burlet P, Liu Q, Bertrandy S, Clermont O, Munnich A, et al. Correlation between severity and SMN protein level in spinal muscular atrophy. Nat Genet 1997;16:265–269.
9. Angelozzi C, Borgo F, Tiziano FD, Martella A, Neri G, Brahe C. Salbutamol increases SMN mRNA and protein levels in spinal muscular atrophy cells. J Med Genet 2008;45:29–31.
10. Tiziano FD, Lomastro R, Pinto AM, Messina S, D'Amico A, Fiori S, et al. Salbutamol increases survival motor neuron (SMN) transcript levels in leucocytes of spinal muscular atrophy (SMA) patients: relevance for clinical trial design. J Med Genet 2010;47:856–858.
11. Sanchez AM, Collomp K, Carra J, Borrani F, Coste O, Préfaut C, et al. Effect of acute and short-term oral salbutamol treatments on maximal power output in non-asthmatic athletes. Eur J Appl Physiol 2012;112:3251–3258.
12. Morandi L, Abiusi E, Pasanisi MB, Lomastro R, Fiori S, Di Pietro L, et al. Salbutamol tolerability and efficacy in adult type III SMA patients: results of a multicentric, molecular and clinical, double-blind, placebo-controlled study. Neuromuscul Disord 2013;23:771.
13. Montes J, Gordon AM, Pandya S, De Vivo DC, Kaufmann P. Clinical outcome measures in spinal muscular atrophy. J Child Neurol 2009;24:968–978.
14. Pasanisi MB, Giovannetti AM, Bussolino C, Campanella A, Leonardi M, Morandi L, et al. Perception of efficacy in adult patients affected by spinal muscular atrophy (SMA) treated with salbutamol. Neuromuscul Disord 2014;24:914.
15. Ustun TB, Chatterji S, Kostanjsek N, Rehm J, Kennedy C, Epping-Jordan J, et al. Developing the World Health Organization Disability Assessment Schedule 2.0. Bull World Health Organ 2010;88:815–823.
16. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The Fatigue Severity Scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989;46:1121–1123.
17. Sprangers MAG, Schwartz CE. Integrating response shift into health related quality of life research: a theoretical model. Soc Sci Med 1999;48:1507–1515.
18. Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol 2006;3:77–101.
19. Lewins A, Silver C. Using software in qualitative research: a step-by-step guide. Thousand Oaks, CA: Sage; 2007.
20. World Health Organization. International Classification of Functioning, Disability and Health. http://www.who.int/classifications/icf/en/. Accessed February 10, 2015.
21. World Health Organization. World Health Organization Disability Assessment Schedule II (WHODAS II). 2001. http://www.who.int/icidh/whodas/index.html. Accessed February 10, 2015.
22. Werlauff U, Højberg A, Firla-Holme R, Steffensen BF, Vissing J. Fatigue in patients with spinal muscular atrophy type II and congenital myopathies: evaluation of the fatigue severity scale. Qual Life Res 2014;23:1479–1488.
23. Brody D, Miller S, Lerman C, Smith D, Caputo G. Patient perception of involvement in medical care: relationship to illness attitudes and outcomes. J Gen Intern Med 1989;4:506–511.
24. Taylor TR. Understanding the choices that patients make. J Am Board Fam Pract 2000;13:124–133.
25. Anderson RB, Hollenberg NK, Williams GH. Physical Symptoms Distress Index: a sensitive tool to evaluate the impact of pharmacological agents on quality of life. Arch Intern Med 1999;159:693–700.
26. Awad AG, Voruganti LN. Quality of life and new antipsychotics in schizophrenia. Are patients better off? Int J Soc Psychiatry 1999;45:268–275.
27. Diamond R. Drugs and the quality of life: the patient's point of view. J Clin Psychiatry 1985;46:29–35.